GlassScriptPhysician profile
Kristin Wilson
NPI 1376792192
$4,953.48
in general payments reported to CMS, 2019-2025
29 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,208 · 2022: $1,357 · 2023: $858 · 2024: $944 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,388.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $650.77 | 2023-2024 | Roxybond |
| Amgen INC. | $520.09 | 2021-2023 | Aimovig |
| Nevro Corp. | $469.09 | 2021-2023 | Senza |
| Scilex Pharmaceuticals INC. | $396.29 | 2021-2025 | Ztlido |
| Medtronic, INC. | $334.45 | 2022-2024 | Intellis Adaptivestim |
| Abbott Laboratories | $327.74 | 2023-2025 | Proclaim, Eterna |
| Abbvie INC. | $315.18 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $286.68 | 2021 | |
| Boston Scientific Corporation | $268.07 | 2022-2025 | Intracept, Patient Trial Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $215.69 | 2022 | |
| Pfizer INC. | $201.63 | 2021-2025 | |
| Averitas Pharma INC. | $119.16 | 2023-2025 | Qutenza |
| Collegium Pharmaceutical, INC. | $115.18 | 2021-2023 | Belbuca |
| Ossur Americas, INC. | $112.03 | 2025 | Unloader One X |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.86 | 2022-2025 | Relistor |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $71.97 | 2025 | Sprint Pns System |
| Lilly USA, LLC | $70.41 | 2021-2023 | Reyvow, Emgality |
| Biodelivery Sciences International, INC. | $53.37 | 2021 | |
| Horizon Therapeutics Plc | $48.33 | 2022 | |
| Supernus Pharmaceuticals, INC. | $48.13 | 2021 | |
| Redhill Biopharma INC. | $47.90 | 2021 | |
| Grt US Holding, INC. | $45.60 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $43.47 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $30.71 | 2023 | Zilretta, Iovera |
| Ibsa Pharma INC. | $22.12 | 2022 | |
| Nalu Medical, INC. | $16.07 | 2023 | Nalu Neurostimulation System |
| Kowa Pharmaceuticals America, INC. | $13.82 | 2022 | |
| Almatica Pharma LLC | $12.96 | 2021 | |
| Mdd US Operations, LLC | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.